Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 14;25(16):3708.
doi: 10.3390/molecules25163708.

Synthesis and Antiviral Evaluation of 3'-Fluoro-5'-norcarbocyclic Nucleoside Phosphonates Bearing Uracil and Cytosine as Potential Antiviral Agents

Affiliations

Synthesis and Antiviral Evaluation of 3'-Fluoro-5'-norcarbocyclic Nucleoside Phosphonates Bearing Uracil and Cytosine as Potential Antiviral Agents

Pierre-Yves Geant et al. Molecules. .

Abstract

Carbocyclic nucleoside analogues are an essential class of antiviral agents and are commonly used in the treatment of viral diseases (hepatitis B, AIDS). Recently, we reported the racemic synthesis and the anti-human immunodeficiency virus activities (HIV) of 3'-fluoro-5'-norcarbocyclic nucleoside phosphonates bearing purines as heterocyclic base. Based on these results, the corresponding racemic norcarbocyclic nucleoside phosphonates bearing pyrimidine bases were synthesized. The prepared compounds were evaluated against HIV, but none of them showed marked antiviral activity compared to their purine counterparts.

Keywords: antiviral; carbocyclic; nucleoside analogues; phosphonates.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Example of antiviral carbocyclic nucleosides and structures of the target compounds.
Scheme 1
Scheme 1
Reagents and conditions: (a) DPPA, DIAD, PPh3, THF/CH2Cl2, 0 °C, 30 min, 67%. (b) LiAlH4, THF, 0 °C to RT, 30 min, 84%. (c) (E)-3-ethoxyacryloyl chloride, AgOCN, toluene, reflux, 30 min; then (±)-5, DMF, −20 °C to RT, 5 h, 98%. (d) HCl (2N), EtOH, reflux, 12 h, 78%.
Scheme 2
Scheme 2
Reagents and conditions: (a) (i) BzOH, DIAD, PPh3, THF, RT, 1 h; (ii) K2CO3, MeOH, RT, 4 h, 93% over two steps. (b) (EtO)2P(O)CH2OTs, NaH, DMF, RT, 3 days. (c) TMSBr, DMF, RT, 24 h, 24% from (±)-8.
Scheme 3
Scheme 3
Reagents and conditions: (a) Ac2O, DMAP, NEt3, THF, RT, 1 h, 77%. (b) (i) Lawesson’s reagent, 1,2-dichloroethane, 83 °C, 20 h; (ii) methanolic ammonia, 100 °C, 4 h, 78% over two steps. (c) (i) BzOH, DIAD, PPh3, THF, RT, 2 h; (ii) K2CO3, MeOH, RT, 2 h, 60% over two steps. (d) Bz2O, DMF, RT, 24 h, 44%. (e) (i) (EtO)2P(O)CH2OTs, LiOtBu, DMF, 40 °C, 1 h; (ii) TMSBr, DMF, RT, 24 h; (iii) methanolic ammonia, 50 °C, 4 h, 67% over three steps.

Similar articles

Cited by

References

    1. De Clercq E., Li G. Approved antiviral drugs over the past 50 years. Clin. Microb. Rev. 2016;29:695–747. doi: 10.1128/CMR.00102-15. - DOI - PMC - PubMed
    1. Seley-Radtke K.L., Yates M.K. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antivir. Res. 2018;154:66–86. doi: 10.1016/j.antiviral.2018.04.004. - DOI - PMC - PubMed
    1. Yates M.K., Seley-Radtke K.L. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antivir. Res. 2019;162:5–21. doi: 10.1016/j.antiviral.2018.11.016. - DOI - PMC - PubMed
    1. Uttaro J.-P., Broussous S., Mathe C., Perigaud C. Synthesis of novel 3′-methyl-5′-norcarbocyclic nucleoside phosphonates as potential anti-HIV agents. Tetrahedron. 2013;69:2131–2136. doi: 10.1016/j.tet.2013.01.011. - DOI
    1. Geant P.Y., Kaci M., Uttaro J.P., Perigaud C., Mathe C. Synthesis and Antiviral Evaluation of 3′-Fluoro-4′-modified-5′-norcarbocyclic Nucleoside Phosphonates. ChemMedChem. 2019;14:522–526. doi: 10.1002/cmdc.201800804. - DOI - PubMed

Publication types

Grants and funding